ReviewBritish journal of pharmacology2010
The endocannabinoid system as a target for the treatment of neurodegenerative disease.
Review in British journal of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cannabinoids for the treatment of dementia.The Cochrane database of systematic reviews · 2021Pooled it
- Cannabinoids in neuropathic pain treatment: pharmacological insights and clinical outcomes from recent trials.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Oral cannabidiol did not impair learning and memory in healthy adults.Journal of cannabis research · 2025Article
- Commentary on the Role of Medicinal Cannabis in Healthy Aging and Neuroprotection.Current medicinal chemistry · 2025Article
- Acute Effects of Monoacylglycerol Lipase Inhibitor ABX1431 on Neuronal Hyperexcitability, Nociception, Locomotion, and the Endocannabinoid System in HIV-1 Tat Male Mice.Cannabis and cannabinoid research · 2024Article
- Therapeutic Application of Modulators of Endogenous Cannabinoid System in Parkinson's Disease.International journal of molecular sciences · 2024Review
- Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.International journal of molecular sciences · 2024Review
- Syntheses of Cannabinoid Metabolites: Ajulemic Acid and HU-210.Molecules (Basel, Switzerland) · 2024Article
- Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer's Disease.Current drug research reviews · 2024Review
- Amyotrophic Lateral Sclerosis and Pain: A Narrative Review from Pain Assessment to Therapy.Behavioural neurology · 2024Review
- A helping HAND: therapeutic potential of MAGL inhibition against HIV-1-associated neuroinflammation.Frontiers in immunology · 2024Article
- Article
- EVs-mediated delivery of CB2 receptor agonist for Alzheimer's disease therapy.Asian journal of pharmaceutical sciences · 2023Article
- Axially Chiral Cannabinoids: Design, Synthesis, and Cannabinoid Receptor Affinity.Journal of the American Chemical Society · 2023Article
- Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation.Frontiers in behavioral neuroscience · 2023Review
- Alcohol induced behavioral and immune perturbations are attenuated by activation of CB2 cannabinoid receptors.Advances in drug and alcohol research · 2023Article
- Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice.International journal of molecular sciences · 2022Article
- Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential.Biomedicines · 2022Review
- Insight into the Inhibitory Mechanism of Aryl Formyl Piperidine Derivatives on Monoacylglycerol Lipase through Molecular Dynamics Simulations.Molecules (Basel, Switzerland) · 2022Article
- Non-psychotropic Cannabis sativa L. phytocomplex modulates microglial inflammatory response through CB2 receptors-, endocannabinoids-, and NF-κB-mediated signaling.Phytotherapy research : PTR · 2022Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The Cannabis sativa plant has been exploited for medicinal, agricultural and spiritual purposes in diverse cultures over thousands of years. Cannabis has been used recreationally for its psychotropic properties, while effects such as stimulation of appetite, analgesia and anti-emesis have lead to the medicinal application of cannabis. Indeed, reports of medicinal efficacy of cannabis can been traced back as far as 2700 BC, and even at that time reports also suggested a neuroprotective effect of the cultivar. The discovery of the psychoactive component of cannabis resin, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) occurred long before the serendipitous identification of a G-protein coupled receptor at which Delta(9)-THC is active in the brain. The subsequent finding of endogenous cannabinoid compounds, the synthesis of which is directed by neuronal excitability and which in turn served to regulate that excitability, further widened the range of potential drug targets through which the endocannabinoid system can be manipulated. As a result of this, alterations in the endocannabinoid system have been extensively investigated in a range of neurodegenerative disorders. In this review we examine the evidence implicating the endocannabinoid system in the cause, symptomatology or treatment of neurodegenerative disease. We examine data from human patients and compare and contrast this with evidence from animal models of these diseases. On the basis of this evidence we discuss the likely efficacy of endocannabinoid-based therapies in each disease context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.